The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.

A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

TUESDAY, July 23, 2024 (HealthDay News) -- The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs’ original purpose, which was to treat type 2 ...

Our study results are the strongest evidence to date that GLP-1 agonist drugs are largely safe and effective tools for addressing type 2 diabetes in kidney transplant recipients." ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...

Overall, 188 people returned for at least one follow-up visit. And people who drank alcohol reported drinking less on average after starting a GLP-1 drug.

While GLP-1 use may be temporary, the mindset shift is likely long-term. Consumers who start their weight loss journey with these medications are developing new habits and looking for products to ...

There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight-loss drug in 2021.